ARCHIVES

Hearing Scheduled To Investigate ImClone’s C225 Development, Stock Trading

This article is from The Cancer Letter archive.

Vol. 28 No. 23 | June 7, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: Sullivan Will Be Secretary Most Knowledgeable About Cancer Program; Ihde Names ‘JNCI’ Editor

January 6, 1989

FDA Auditors Spend Two Weeks At Duke, Nevins Loses Position in Reorganization

January 28, 2011

NCI-Approved Clinical Trials

June 30, 2006

Patients on Hypertension Meds Lived Longer, Analysis Shows

January 31, 2014

John Niederhuber Named Acting NCI Director.

June 2, 2006

Sharp To Direct New Institute For Brain Research At MIT.

March 3, 2000